Celgene Corporation (NASDAQ:CELG) Gets FDA Fast Track Designation For Two Trials

Celgene Corporation (NASDAQ:CELG) collaborations have been benefiting the company, and the U.S. Food and Drug Administration has given a green signal to two of its projects. Reportedly, the drug deals with Agios Pharmaceuticals Inc (NASDAQ:AGIO) and Acceleron Pharma Inc (NASDAQ:XLRN) are set to reach their final trials after the regulatory nod. The FDA has added […]

Pfizer Inc. (NYSE:PFE) Taps New R&D Leaders As Gutiérrez-Ramos Heads Back Into Biotech

Pfizer Inc. (NYSE:PFE) is in unchartered waters following the news about the exit of the company’s CEO, José-Carlos Gutiérrez-Ramos. Gutiérrez-Ramos, who is renowned for his leadership in the Bio Therapeutics research and development department in Cambridge, MA, will leave Pfizer in search of greener pastures. Word has it that he will leave the pharmaceuticals company […]

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time

Celgene Corporation (NASDAQ:CELG) is deepening its ties with biotech company Agios Pharmaceuticals Inc (NASDAQ:AGIO) with a 50-50 collaboration on another preclinical cancer candidate. Celgene will give $10 million up front and promises up to $70 million more to get a share of AG-881. AG-881 is Agios’ therapy that aims to target cancer metabolism with the […]

Celgene Corporation (NASDAQ:CELG) to buy Cancer research Company Quanticel Pharmaceuticals

Celgene Corporation (NASDAQ:CELG) is buying up Quanticel Pharmaceuticals for a deal worth $485 million. The deal comes after Clegene teamed up with Versant Ventures to help Quanticel get off the ground Quanticel is a cancer focused biotech and has a drug recover engine that uses single cell genomic analysis to decode cancer cells and highlight […]